Your browser is no longer supported. Please, upgrade your browser.
Settings
BVXV BiondVax Pharmaceuticals Ltd. daily Stock Chart
BVXV [NASD]
BiondVax Pharmaceuticals Ltd.
Index- P/E- EPS (ttm)-4.69 Insider Own22.93% Shs Outstand7.00M Perf Week12.31%
Market Cap80.58M Forward P/E- EPS next Y-0.07 Insider Trans0.00% Shs Float5.14M Perf Month51.47%
Income-32.40M PEG- EPS next Q-0.03 Inst Own6.60% Short Float0.58% Perf Quarter109.30%
Sales- P/S- EPS this Y-95.30% Inst Trans- Short Ratio0.90 Perf Half Y91.54%
Book/sh-0.63 P/B- EPS next Y-16.70% ROA-111.90% Target Price30.00 Perf Year108.92%
Cash/sh3.11 P/C3.70 EPS next 5Y- ROE289.40% 52W Range4.65 - 13.50 Perf YTD23.91%
Dividend- P/FCF- EPS past 5Y-14.60% ROI- 52W High-14.22% Beta1.35
Dividend %- Quick Ratio25.10 Sales past 5Y- Gross Margin- 52W Low149.03% ATR0.94
Employees17 Current Ratio25.10 Sales Q/Q- Oper. Margin- RSI (14)67.73 Volatility7.93% 9.71%
OptionableNo Debt/Eq- EPS Q/Q-494.90% Profit Margin- Rel Volume1.44 Prev Close11.51
ShortableYes LT Debt/Eq- EarningsFeb 25 BMO Payout- Avg Volume32.89K Price11.58
Recom- SMA2015.65% SMA5047.94% SMA20078.16% Volume32,424 Change0.60%
Jan-16-20 03:05PM  BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis PR Newswire -6.48%
Dec-04-19 08:25AM  BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled Zacks Small Cap Research
Nov-26-19 07:00AM  BiondVax Announces Third Quarter 2019 Financial Results and Business Update PR Newswire
Nov-18-19 07:15AM  Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial PR Newswire
Nov-11-19 08:14AM  Do Directors Own BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Shares? Simply Wall St. +6.02%
Oct-07-19 09:15AM  BiondVax Receives 4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial PR Newswire
Aug-28-19 07:45AM  BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results PR Newswire
Aug-01-19 10:00AM  BVXV: Raises $20 Million; Phase 3 Trial Fully Funded Zacks Small Cap Research
Jul-16-19 07:30AM  BiondVax Announces Rights Offering Fully Subscribed at US$20 Million PR Newswire
Jul-08-19 05:45AM  First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial PR Newswire
Jun-26-19 10:51AM  European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to 24million PR Newswire
Jun-25-19 09:37AM  BiondVax Gets OK to Build Plant in Israel (BVXV) Investopedia
Jun-18-19 06:30AM  Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan PR Newswire
Jun-12-19 03:30PM  BVXV: Rights Offering to Finance Company Through Phase 3 Trial Results Zacks Small Cap Research
Jun-10-19 08:18AM  BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process PR Newswire
May-30-19 07:10AM  BiondVax Announces First Quarter 2019 Financial Results PR Newswire -7.51%
May-13-19 07:00AM  BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference PR Newswire
Apr-30-19 04:01PM  BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update PR Newswire
Apr-22-19 08:10AM  European Investment Bank (EIB) Extends Financing Agreement to 24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial PR Newswire -5.96%
Apr-17-19 01:00PM  BVXV: Update on Phase 3 Clinical Trial of Universal Influenza Vaccine Zacks Small Cap Research
Apr-15-19 07:50AM  BiondVax Universal Flu Vaccine Patent Application Accepted in Australia PR Newswire
Mar-28-19 07:30AM  BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference PR Newswire +5.90%
Mar-21-19 07:00AM  Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate PR Newswire
Nov-28-18 07:40AM  Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-26-18 07:00AM  BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate PR Newswire -7.25%
Nov-20-18 11:00AM  BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine Zacks Small Cap Research
Nov-19-18 07:00AM  BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results PR Newswire
Nov-13-18 04:01PM  BiondVax Announces Third Quarter 2018 Financial Results PR Newswire
Oct-24-18 07:00AM  BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants PR Newswire
Oct-22-18 08:00AM  BiondVax Receives 8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial PR Newswire
Oct-17-18 08:15AM  Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-05-18 09:30AM  BVXV: Phase 3 Trial of M-001 Underway Zacks Small Cap Research
Sep-04-18 06:15AM  BiondVax to Present at Influenza 2018 Oxford Conference PR Newswire
Aug-22-18 07:00AM  BiondVax Announces Second Quarter 2018 Financial Results PR Newswire +5.83%
Aug-20-18 07:50AM  Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:00AM  BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility PR Newswire
Aug-14-18 06:00AM  BiondVax Receives Second 6M Tranche Disbursement From the European Investment Bank (EIB) PR Newswire
Aug-08-18 08:30AM  First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial PR Newswire
Jun-28-18 07:00AM  Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors PR Newswire
Jun-19-18 09:00AM  BiondVax Receives Its First 6M Tranche Disbursement From the European Investment Bank (EIB) PR Newswire
Jun-05-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Jun-01-18 10:30AM  BVXV: Increased Media Coverage for M-001 Ahead of Phase 3 Clinical Trial Zacks Small Cap Research
May-29-18 07:00AM  BiondVax Announces First Quarter 2018 Financial Results PR Newswire
May-07-18 09:45AM  BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18 Zacks Small Cap Research
Apr-30-18 04:05PM  BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update PR Newswire
Apr-13-18 07:20AM  Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US ACCESSWIRE
Apr-12-18 06:30AM  BiondVax to Present at Universal Influenza Vaccines Conference PR Newswire
Apr-11-18 07:45AM  BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States PR Newswire
Apr-09-18 08:15AM  Recent Analysis Shows Norbord, BiondVax Pharmaceuticals, NXP Semiconductors N.V, Lazard, Canadian Solar, and Sierra Wireless Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -5.13%
Mar-15-18 08:25AM  Recent Analysis Shows KB Financial Group, Southern Missouri, Net 1 UEPS Technologies, Financial Engines, Carbonite, and BiondVax Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-13-18 09:00AM  BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate PR Newswire
Feb-08-18 08:30AM  BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference PR Newswire -6.97%
Jan-02-18 09:00AM  BiondVax Universal Flu Vaccine Patent Granted in India PR Newswire
Dec-27-17 09:00AM  BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA) PR Newswire
Dec-12-17 12:00PM  BVXV: Planning Continues for M-001 Phase 3 Program Zacks Small Cap Research
Dec-11-17 07:30AM  Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders ACCESSWIRE
Dec-05-17 09:00AM  BiondVax's CEO Issues Letter to Shareholders PR Newswire
Nov-28-17 09:00AM  BiondVax Provides Third Quarter 2017 Financial Results and Update PR Newswire
Nov-20-17 09:00AM  BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine PR Newswire
Sep-20-17 01:00PM  BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine Zacks Small Cap Research
Sep-18-17 11:35AM  BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option PR Newswire
Sep-13-17 08:25PM  BiondVax Announces Pricing of Public Offering of American Depositary Shares PR Newswire
04:55PM  BiondVax Announces Public Offering of American Depositary Shares PR Newswire
11:07AM  Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)? Simply Wall St.
Sep-12-17 07:15AM  Featured Company News - Oncobiologics Announces Partnership with GMS Tenshi Holdings; Set to Accelerate the Commercialization of Biosimilar Candidates ACCESSWIRE
Aug-31-17 07:30AM  Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange PR Newswire
07:30AM  BiondVax Provides Second Quarter 2017 Financial Results and Update PR Newswire
Aug-14-17 08:00AM  BiondVax Receives Additional Grant Funding PR Newswire
Aug-01-17 01:00PM  BVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza Vaccine Zacks Small Cap Research
Jul-20-17 06:30AM  BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine PR Newswire
Jul-18-17 07:30AM  BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine PR Newswire
Jul-06-17 01:00PM  BVXV: Secures $22 Million Loan Agreement with European Investment Bank Zacks Small Cap Research
Jun-28-17 04:01PM  BiondVax's CEO Provides First Half 2017 General Corporate Update PR Newswire
Jun-19-17 07:00AM  European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative PR Newswire
Jun-12-17 08:15AM  Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials Accesswire
Jun-02-17 01:00PM  BVXV: Immunogenicity Results From Phase 2b Trial of M-001 Expected Soon Zacks Small Cap Research
May-30-17 07:00AM  BiondVax Announces First Quarter 2017 Financial Results and Update PR Newswire
May-08-17 03:00PM  BVXV: Awarded Grant to Build Commercial Scale Facility for Production of M-001 Zacks Small Cap Research
Apr-28-17 08:00AM  BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update PR Newswire
Mar-30-17 11:59AM  BiondVax Gets Approval to Build Plant in Israel Investopedia
11:59AM  BiondVax Gets Approval to Build Plant in Israel at Investopedia
02:00AM  BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine PR Newswire
Mar-13-17 09:30AM  BiondVax Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines in Future Virology Journal PR Newswire
Jan-20-17 11:30AM  BVXV: New Publication Shows M-001 Incites Immune Protection Against Current and Future Influenza Strains Zacks Small Cap Research
Jan-12-17 07:00AM  Back to the Future: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't yet Exist PR Newswire
Jan-02-17 03:00AM  BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd. PR Newswire
Dec-01-16 11:00AM  BVXV: Phase 2b Trial Shows M-001 is Safe and Well Tolerated Zacks Small Cap Research
Nov-29-16 07:30AM  BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated PR Newswire
Nov-28-16 08:08AM  BiondVax Announces Third Quarter 2016 Financial Results and Update PR Newswire
Nov-22-16 07:00AM  Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVaxs Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains PR Newswire
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.